Cover Image


Orally Inhaled Bronchodilators to 2022

出版商 Greystone Research Associates 商品編碼 327796
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
口服吸入支氣管擴張劑市場:∼2022年 Orally Inhaled Bronchodilators to 2022
出版日期: 2015年04月06日 內容資訊: 英文




  • 呼吸系統治療藥市場
  • 口服吸入支氣管擴張劑治療目標
  • 競爭的藥物治療
  • 需求促進要素
  • 技術因素
  • 競爭環境


  • 全球患者統計
  • 各地區市場促進要素
  • 兒童氣喘:治療需求擴大


  • dry撲粉
    • DPI製劑
    • 特性和參數
    • DPI賦形劑與包裝
  • 定量吸入器
    • MDI設備選擇標準
    • 可用性的要素
  • 噴霧器



  • 法律規章問題
  • 患者的適合性
  • 處方趨勢
  • 醫療經濟學
  • 各地區市場因素
  • 連網型設備


Product Code: HBD654F

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

Report Highlights

  • Analyzes the market for bronchodilator drugs delivered via oral inhalers
  • Assesses inhalation device technology for delivering bronchodilators orally, and evaluates product technology issues and evolving market factors
  • Provides detailed assessments of orally inhaled bronchodilator product segments, growth prospects and market potential
  • Provides market data and forecasts for orally inhaled bronchodilators to 2022
  • Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
  • Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Report Value Chain - Who Should Read this Report


Table of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

  • The Upper Respiratory Therapeutics Marketspace
  • Therapeutic Targets for Orally Inhaled Bronchodilators
  • Competing Drug Treatments
  • Demand Drivers
  • Technology Factors
  • Competitive Landscape

Asthma Market Risks and Opportunities

  • Global Patient Demographics
  • Regional Market Drivers
  • Pediatric Asthma -the Growing Therapeutic Need

Inhaler Technologies for Delivering Bonchodilators

  • Dry Powder Inhalers
    • DPI Formulation Technology
    • Characteristics and Parameters
    • DPI Excipients and Packaging
  • Metered Dose Inhalers
    • MDI Device Selection Criteria
    • Ease-of-Use Factors
  • Nebulizers

Inhaled Bronchodilators - Product Analysis, Market Data & Forecasts

  • Albuterol, Proventil HFA (MDI)
  • Albuterol, Ventolin HFA (MDI)
  • Albuterol, ProAir HFA (MDI)
  • Albuterol, Accuneb (Nebulizer)
  • Generic Albuterol (Nebulizer)
  • Albuterol/Ipratropium (Combuvent) Combination Drug Inhaler (MDI)
  • Albuterol/Ipratropium (Duoneb) Combination Drug Solution (Nebulizer)
  • Generic Albuterol/Ipratropium Combination Drug Solution (Nebulizer)
  • Fluticasone/Vilanterol (Breo Ellipta) Combination Drug Inhaler (DPI) Fluticasone/Salmeterol (Advair HFA) Combination Drug Inhaler (MDI)
  • Fluticasone/Salmeterol (Advair Diskus) Combination Drug Inhaler (DPI)
  • Formoterol, Foradil (DPI)
  • Formoterol, Perforomist (Nebulizer)
  • Formoterol/Mometasone (Dulera) Combination Drug Inhaler (MDI)
  • Ipratropium, Atrovent HFA (MDI)
  • Generic Ipratropium (Nebulizer)
  • Levalbuterol, Xopenex (Nebulizer)
  • Generic Levalbuterol (Nebulizer)
  • Levalbuterol, Xopenex HFA( MDI)
  • Salmeterol, Serevent (DPI)
  • Tiotropium, Spiriva (DPI)
  • Tiotropium, Spiriva Respimat (MDI)
  • Umeclidinium, Incruse Ellipta (DPI)
  • Umeclidinium/Vilanterol (Anoro) Combination Drug Inhaler (DPI)

Market Factors

  • Regulatory Issues
  • Patient Compliance
  • Prescribing Trends
  • Healthcare Economics
  • Regional Market Factors
  • Connected Devices

Market Sector Company Profiles

Back to Top